TORONTO and HAIFA, Israel, June 04, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce the voting results from its annual general and special meeting of shareholders (“Shareholders”) held on Monday, June 3, 2024 via live webcast (the “Meeting”). Shareholders voted overwhelmingly in favour of each resolution put forth at the Meeting at a passing rate of over 99%.
At the Meeting, there were 41 Shareholders represented in person or by proxy holding 20,329,922 common shares in the capital of the Company (“Common Shares”), representing 30.88% of the Company’s issued and outstanding Common Shares as at the record date for the Meeting, which was 65,830,428 Common Shares.